Prevailing against cost-leader competitors in the pharmaceutical industry

Journal of Generic Medicines

Volumn 5, Issue 4, 2008, Pages 305-314

  Tomer, Gil ^a  

^a Unipharm Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54749125496     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/jgm.2008.15     Document Type: Article

References (26)

1. Comanor, W. S. & Schweitzer, S. O. (2005). Pharmaceuticals, in Adams, W., Brock, J. (eds), The Structure of American Industry, Prentice-Hall, Englewood Cliffs, NJ, pp. 177-196.
2. Kumar, N. (2006). Strategies to fight low-cost rivals. Harv. Bus. Rev. 84(12), 104-112.
3. Stackelberg, H. (1934). Marktform und gleichgewicht, Verlag von Julius Springer, Wien und berlin.
4. Nocera, J. (2006). Generic drugs: The window has loopholes. NY Times. July 1st, 2006.
5. Kamien, M. I. & Zang, I. (1999).Virtual patent extension by cannibalization. South Econ. J. 66(1), 117-131.
6. Cohen, F. J. (2005). Macro trends in pharmaceutical innovation. Drug Discov. 4, 78-84.
7. Liberman, M. B. & Montgomery, D. B. (1988). First-mover advantages. Strategic Manage. J. 9, 41-58.
8. Porter, M. E. (1996). What is strategy? Harv. Bus. Rev. 74 6), 61-78.
9. Dyer, O. (2003). Lundbeck broke advertising rules. BMJ 326, 1004.
10. EP0347066A1: New enantiomers and their isolation, Filling date: June 1989.
11. FDA's orange book, http://www.fda.gov/cder/. accessed 23rd July, 2007.
12. Hellstrom, P. M. & Vitols, S. (2004). The choice of proton pump inhibitor: Does it matter? Basic Clin. Pharmacol. Toxicol. 94 106-111.
13. US5714504: Compositions, Filling date: January 1995.
14. Anonymous (2007). Paliperidone (Invega) for Schizophrenia. Med. Lett. 49(1256), 21-23.
15. US20040092534: Methods and dosage forms for controlled delivery of paliperidone, Filing date: July 2003.
16. US20050208132: Methods and dosage forms for reducing side effects of benzisozazole derivatives, Filing date: February 2005.
17. US20060189635: Enhanced efficacy benzisoxazole derivative dosage forms and methods, Filing date: October 2005.
18. Annual Report 2001, Lundbeck (2001). http://www.materials.lundbeck.com/ lundbeck/81/. accessed July 23, 2007.
19. Goldenberg, J., Horowitz, R., Levav, A. & Mazursky, D. (2003). Finding your innovation sweet spot. Harv. Bus. Rev. 81(3), 120-129.
20. Eisenhardt, K. M. & Brown, S. L. (1998). Time pacing: Competing in markets that won't stand still. Harv. Bus. Rev. March-April.
21. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151-185.
22. GSK's mission, available at: http://www.gsk.com. accessed 23rd July, 2007.
23. Pfizer's mission, available at: http://www.pfizer.com. accessed 23rd July, 2007.
24. Moss, G. (2001). Pharmaceutical brands: Do they really exist? Int. J. Med. Market 2(1), 23-32.
25. Gale, E. M. A. (2007). Dying of diabetes. Lancet 368, 1626-1628.
26. Morgan, S. G., Bassett, K. L., Wright, J. M., Evans, R. G., Barer, M. L., Caetano, P. A., & Black, C. D. (2005). 'Breakthrough' drugs and growth in expenditure on prescription drugs in Canada. BMJ 331 815-816.